The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Physiology - Lung cellular and Molecular Physiology

• Publication date

  2009-07-17

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1152/ajplung.00189.2009PMID 19617308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats.

  2008cited by this paper
• Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature

  2007cited by this paper
• Hypoxia divergently regulates production of reactive oxygen species in human pulmonary and coronary artery smooth muscle cells.

  2007cited by this paper
• Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling

  2006cited by this paper
• Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.

  2006influential reference
• Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange

  2006cited by this paper
• Biochemistry and Pharmacology of Novel Anthranilic Acid Derivatives Activating Heme-Oxidized Soluble Guanylyl Cyclase

  2006influential reference
• NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

  2006cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Congenital erythropoietin over-expression causes “anti-pulmonary hypertensive” structural and functional changes in mice, both in normoxia and hypoxia

  2005cited by this paper
• Oxygen, oxidative stress, hypoxia, and heart failure.

  2005cited by this paper
• Acute oxygen-sensing mechanisms.

  2005cited by this paper
• Hypoxic pulmonary vasoconstriction: redox regulation of O2-sensitive K+ channels by a mitochondrial O2-sensor in resistance artery smooth muscle cells.

  2004cited by this paper
• Adrenomedullin Can Protect Against Pulmonary Vascular Remodeling Induced by Hypoxia

  2004cited by this paper
• Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension

  2004cited by this paper
• Progenitor cells of the testosterone-producing Leydig cells revealed

  2004cited by this paper
• Soluble Guanylate Cyclase Activator Reverses Acute Pulmonary Hypertension and Augments the Pulmonary Vasodilator Response to Inhaled Nitric Oxide in Awake Lambs

  2004cited by this paper
• NO activation of guanylyl cyclase

  2004cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• Basic features of hypoxic pulmonary vasoconstriction in mice.

  2004cited by this paper
• Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species.

  2004cited by this paper
• Oxidative stress in the systemic and cellular responses to intermittent hypoxia

  2004cited by this paper
• Pharmacology and biochemistry of novel compounds activating heme-oxidized soluble guanylyl cyclase

  2003influential reference
• Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase.

  2003cited by this paper
• ROS in the local and systemic pathogenesis of COPD.

  2003cited by this paper
• Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus

  2003cited by this paper
• Essential role of complex II of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature.

  2003cited by this paper
• NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

  2002cited by this paper
• Lessons from chronic intermittent and sustained hypoxia at high altitudes.

  2002cited by this paper
• Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: influence of age and diabetic state.

  2002cited by this paper
• Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders

  2002cited by this paper
• Mitochondrial Reactive Oxygen Species Trigger Calcium Increases During Hypoxia in Pulmonary Arterial Myocytes

  2002cited by this paper
• Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia.

  2001cited by this paper
• Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS.

  2001cited by this paper
• NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs.

  2001cited by this paper
• Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension.

  2001cited by this paper
• eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia.

  2000cited by this paper
• Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

  2000cited by this paper
• The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia.

  1999cited by this paper
• Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia.

  1999cited by this paper
• Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia.

  1999cited by this paper
• The deactivation of soluble guanylyl cyclase by redox-active agents.

  1998cited by this paper
• Oxidative damage and tyrosine nitration from peroxynitrite.

  1996cited by this paper
• Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung.

  1996cited by this paper
• Hypoxic vasoconstriction in buffer-perfused rabbit lungs.

  1995cited by this paper
• The Leydig cell of the human testis —A new member of the diffuse neuroendocrine system

  1993cited by this paper
• Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms.

  1986cited by this paper

• Vascular diameter and responsiveness to soluble guanylate cyclase modulators: A systematic review of preclinical and clinical evidence.

  2025cites this paper
• Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure.

  2025cites this paper
• Factors influencing the soluble Guanylate Cyclase Heme redox state in blood vessels.

  2022cites this paper
• Connexins may play a critical role in cigarette smoke-induced pulmonary hypertension

  2022cites this paper
• IRAG1 Deficient Mice Develop PKG1β Dependent Pulmonary Hypertension

  2020cites this paper
• Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis

  2020cites this paper
• NO‐sensitive guanylyl cyclase in the lung

  2020cites this paper
• Yarsagumba is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties

  2020cites this paper
• Changes in the nitric oxide pathway of the pulmonary vasculature after exposure to hypoxia in swine model of neonatal pulmonary vascular disease

  2018cites this paper
• Elevated Vasodilatory Cyclases and Shorter Telomere Length Contribute to High-Altitude Pulmonary Edema

  2018cites this paper
• Altered Redox Balance in the Development of Chronic Hypoxia-induced Pulmonary Hypertension.

  2017cites this paper
• Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension

  2017cites this paper
• Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension

  2017cites this paper
• Nueva clase de fármacos para la hipertensión arterial pulmonar y la hipertensión pulmonar tromboembólica crónica

  2016cites this paper
• Effect of nitric oxide deficiency on the pulmonary PTHrP system

  2016cites this paper
• The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis.

  2016cites this paper
• Cerebrovascular effects of vasoactive drugs: in vitro, in vivo and clinical investigations

  2015cites this paper
• Extending the translational potential of targeting NO/cGMP‐regulated pathways in the CVS

  2015cites this paper
• Soluble Guanylate Cyclase: A New Therapeutic Target for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

  2015cites this paper
• Rôle de SIRT1 et de la biogenèse mitochondriale dans la prolifération des cellules du muscle lisse de l'artère pulmonaire

  2015cites this paper
• Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema.

  2014cites this paper
• Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.

  2014cites this paper
• Oxidative Stress and Therapeutic Development in Lung Diseases

  2014cites this paper
• The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice.

  2014cites this paper
• ADMA metabolism and chronic hypoxia-induced pulmonary hypertenstion

  2014cites this paper
• A Molecular Mechanism for Therapeutic Effects of cGMP-elevating Agents in Pulmonary Arterial Hypertension*

  2013cites this paper
• Validation of phosphodiesterase isozymes as targets for pulmonary hypertension.

  2013cites this paper
• Measurement of right ventricular pressure by telemetry in conscious moving rabbits

  2013cites this paper
• sGC stimulation totally reverses hypoxia‐induced pulmonary vasoconstriction alone and combined with dual endothelin‐receptor blockade in a porcine model

  2012cites this paper
• Pulmonary hypertension: have we learned enough yet?

  2012cites this paper
• Persistent vascular collagen accumulation alters hemodynamic recovery from chronic hypoxia.

  2012cites this paper
• Activation of Haem-Oxidized Soluble Guanylyl Cyclase with BAY 60-2770 in Human Platelets Lead to Overstimulation of the Cyclic GMP Signaling Pathway

  2012cites this paper
• The role of isoforms of soluble guanylyl cyclase in relaxation of vascular smooth muscle cells and corpora cavernosa

  2012cites this paper
• Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension

  2011cites this paper
• Telemetric left ventricular monitoring using wireless telemetry in the rabbit model

  2011cites this paper
• Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.

  2011cites this paper
• New perspectives for the treatment of pulmonary hypertension

  2011cites this paper
• Pulmonary hypertension: advances in pathogenesis and treatment.

  2010cites this paper
• Inhalational therapy for pulmonary arterial hypertension: current status and future prospects.

  2010cites this paper
• The PPARβ/δAgonist GW0742 Relaxes Pulmonary Vessels and Limits Right Heart Hypertrophy in Rats with Hypoxia-Induced Pulmonary Hypertension

  2010cites this paper
• Heme-Dependent and Independent Soluble Guanylate Cyclase Activators and Vasodilation

  2010cites this paper
• Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension

  2010cites this paper
• Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.

  2010cites this paper